Existing plaques and neuritic abnormalities in APP: PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575

Monica Garcia-Alloza, Meenakshi Subramanian, Diana Thyssen, Laura A. Borrelli, Abdul Fauq, Pritam Das, Todd E. Golde, Bradley T. Hyman, Brian J. Bacskai

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The -secretase complex is a major therapeutic target for the prevention and treatment of Alzheimer's disease. Previous studies have shown that treatment of young APP mice with specific inhibitors of -secretase prevented formation of new plaques. It has not yet been shown directly whether existing plaques would be affected by -secretase inhibitor treatment. Similarly, alterations in neuronal morphology in the immediate vicinity of plaques represent a plaque-specific neurotoxic effect. Reversal of these alterations is an important endpoint of successful therapy whether or not a treatment affects plaque size. In the present study we used longitudinal imaging in vivo with multiphoton microscopy to study the effects of the orally active -secretase inhibitor LY-411575 in 10-11 month old APP:PS1 mice with established amyloid pathology and neuritic abnormalities. Neurons expressed YFP allowing fluorescent detection of morphology whereas plaques were labelled with methoxy-XO4. The same identified neurites and plaques were followed in weekly imaging sessions in living mice treated daily (5 mg/kg) for 3 weeks with the compound. Although LY-411575 reduced A levels in plasma and brain, it did not have an effect on the size of existing plaques. There was also no effect on the abnormal neuritic curvature near plaques, or the dystrophies in very close proximity to senile plaques. Our results suggest that therapeutics aimed at inhibition of A generation are less effective for reversal of existing plaques than for prevention of new plaque formation and have no effect on the plaque-mediated neuritic abnormalities, at least under these conditions where A production is suppressed but not completely blocked. Therefore, a combination therapy of A suppression with agents that increase clearance of amyloid and/or prevent neurotoxicity might be needed for a more effective treatment in patients with pre-existing pathology.

Original languageEnglish (US)
Article number19
JournalMolecular Neurodegeneration
Volume4
Issue number1
DOIs
StatePublished - 2009

Fingerprint

N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
Amyloid Precursor Protein Secretases
Amyloid Plaques
Amyloid
Therapeutics
Pathology
Neurites
Longitudinal Studies
Microscopy
Alzheimer Disease

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Clinical Neurology
  • Molecular Biology

Cite this

Existing plaques and neuritic abnormalities in APP : PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. / Garcia-Alloza, Monica; Subramanian, Meenakshi; Thyssen, Diana; Borrelli, Laura A.; Fauq, Abdul; Das, Pritam; Golde, Todd E.; Hyman, Bradley T.; Bacskai, Brian J.

In: Molecular Neurodegeneration, Vol. 4, No. 1, 19, 2009.

Research output: Contribution to journalArticle

Garcia-Alloza, M, Subramanian, M, Thyssen, D, Borrelli, LA, Fauq, A, Das, P, Golde, TE, Hyman, BT & Bacskai, BJ 2009, 'Existing plaques and neuritic abnormalities in APP: PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575', Molecular Neurodegeneration, vol. 4, no. 1, 19. https://doi.org/10.1186/1750-1326-4-19
Garcia-Alloza, Monica ; Subramanian, Meenakshi ; Thyssen, Diana ; Borrelli, Laura A. ; Fauq, Abdul ; Das, Pritam ; Golde, Todd E. ; Hyman, Bradley T. ; Bacskai, Brian J. / Existing plaques and neuritic abnormalities in APP : PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. In: Molecular Neurodegeneration. 2009 ; Vol. 4, No. 1.
@article{ec324f5d2b64446f9dca5b2be9b703f8,
title = "Existing plaques and neuritic abnormalities in APP: PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575",
abstract = "The -secretase complex is a major therapeutic target for the prevention and treatment of Alzheimer's disease. Previous studies have shown that treatment of young APP mice with specific inhibitors of -secretase prevented formation of new plaques. It has not yet been shown directly whether existing plaques would be affected by -secretase inhibitor treatment. Similarly, alterations in neuronal morphology in the immediate vicinity of plaques represent a plaque-specific neurotoxic effect. Reversal of these alterations is an important endpoint of successful therapy whether or not a treatment affects plaque size. In the present study we used longitudinal imaging in vivo with multiphoton microscopy to study the effects of the orally active -secretase inhibitor LY-411575 in 10-11 month old APP:PS1 mice with established amyloid pathology and neuritic abnormalities. Neurons expressed YFP allowing fluorescent detection of morphology whereas plaques were labelled with methoxy-XO4. The same identified neurites and plaques were followed in weekly imaging sessions in living mice treated daily (5 mg/kg) for 3 weeks with the compound. Although LY-411575 reduced A levels in plasma and brain, it did not have an effect on the size of existing plaques. There was also no effect on the abnormal neuritic curvature near plaques, or the dystrophies in very close proximity to senile plaques. Our results suggest that therapeutics aimed at inhibition of A generation are less effective for reversal of existing plaques than for prevention of new plaque formation and have no effect on the plaque-mediated neuritic abnormalities, at least under these conditions where A production is suppressed but not completely blocked. Therefore, a combination therapy of A suppression with agents that increase clearance of amyloid and/or prevent neurotoxicity might be needed for a more effective treatment in patients with pre-existing pathology.",
author = "Monica Garcia-Alloza and Meenakshi Subramanian and Diana Thyssen and Borrelli, {Laura A.} and Abdul Fauq and Pritam Das and Golde, {Todd E.} and Hyman, {Bradley T.} and Bacskai, {Brian J.}",
year = "2009",
doi = "10.1186/1750-1326-4-19",
language = "English (US)",
volume = "4",
journal = "Molecular Neurodegeneration",
issn = "1750-1326",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Existing plaques and neuritic abnormalities in APP

T2 - PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575

AU - Garcia-Alloza, Monica

AU - Subramanian, Meenakshi

AU - Thyssen, Diana

AU - Borrelli, Laura A.

AU - Fauq, Abdul

AU - Das, Pritam

AU - Golde, Todd E.

AU - Hyman, Bradley T.

AU - Bacskai, Brian J.

PY - 2009

Y1 - 2009

N2 - The -secretase complex is a major therapeutic target for the prevention and treatment of Alzheimer's disease. Previous studies have shown that treatment of young APP mice with specific inhibitors of -secretase prevented formation of new plaques. It has not yet been shown directly whether existing plaques would be affected by -secretase inhibitor treatment. Similarly, alterations in neuronal morphology in the immediate vicinity of plaques represent a plaque-specific neurotoxic effect. Reversal of these alterations is an important endpoint of successful therapy whether or not a treatment affects plaque size. In the present study we used longitudinal imaging in vivo with multiphoton microscopy to study the effects of the orally active -secretase inhibitor LY-411575 in 10-11 month old APP:PS1 mice with established amyloid pathology and neuritic abnormalities. Neurons expressed YFP allowing fluorescent detection of morphology whereas plaques were labelled with methoxy-XO4. The same identified neurites and plaques were followed in weekly imaging sessions in living mice treated daily (5 mg/kg) for 3 weeks with the compound. Although LY-411575 reduced A levels in plasma and brain, it did not have an effect on the size of existing plaques. There was also no effect on the abnormal neuritic curvature near plaques, or the dystrophies in very close proximity to senile plaques. Our results suggest that therapeutics aimed at inhibition of A generation are less effective for reversal of existing plaques than for prevention of new plaque formation and have no effect on the plaque-mediated neuritic abnormalities, at least under these conditions where A production is suppressed but not completely blocked. Therefore, a combination therapy of A suppression with agents that increase clearance of amyloid and/or prevent neurotoxicity might be needed for a more effective treatment in patients with pre-existing pathology.

AB - The -secretase complex is a major therapeutic target for the prevention and treatment of Alzheimer's disease. Previous studies have shown that treatment of young APP mice with specific inhibitors of -secretase prevented formation of new plaques. It has not yet been shown directly whether existing plaques would be affected by -secretase inhibitor treatment. Similarly, alterations in neuronal morphology in the immediate vicinity of plaques represent a plaque-specific neurotoxic effect. Reversal of these alterations is an important endpoint of successful therapy whether or not a treatment affects plaque size. In the present study we used longitudinal imaging in vivo with multiphoton microscopy to study the effects of the orally active -secretase inhibitor LY-411575 in 10-11 month old APP:PS1 mice with established amyloid pathology and neuritic abnormalities. Neurons expressed YFP allowing fluorescent detection of morphology whereas plaques were labelled with methoxy-XO4. The same identified neurites and plaques were followed in weekly imaging sessions in living mice treated daily (5 mg/kg) for 3 weeks with the compound. Although LY-411575 reduced A levels in plasma and brain, it did not have an effect on the size of existing plaques. There was also no effect on the abnormal neuritic curvature near plaques, or the dystrophies in very close proximity to senile plaques. Our results suggest that therapeutics aimed at inhibition of A generation are less effective for reversal of existing plaques than for prevention of new plaque formation and have no effect on the plaque-mediated neuritic abnormalities, at least under these conditions where A production is suppressed but not completely blocked. Therefore, a combination therapy of A suppression with agents that increase clearance of amyloid and/or prevent neurotoxicity might be needed for a more effective treatment in patients with pre-existing pathology.

UR - http://www.scopus.com/inward/record.url?scp=66749116755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66749116755&partnerID=8YFLogxK

U2 - 10.1186/1750-1326-4-19

DO - 10.1186/1750-1326-4-19

M3 - Article

C2 - 19419556

AN - SCOPUS:66749116755

VL - 4

JO - Molecular Neurodegeneration

JF - Molecular Neurodegeneration

SN - 1750-1326

IS - 1

M1 - 19

ER -